全文获取类型
收费全文 | 221311篇 |
免费 | 18030篇 |
国内免费 | 4643篇 |
专业分类
耳鼻咽喉 | 1516篇 |
儿科学 | 4732篇 |
妇产科学 | 2514篇 |
基础医学 | 12906篇 |
口腔科学 | 2530篇 |
临床医学 | 24413篇 |
内科学 | 24951篇 |
皮肤病学 | 2605篇 |
神经病学 | 9095篇 |
特种医学 | 4080篇 |
外国民族医学 | 9篇 |
外科学 | 15489篇 |
综合类 | 37253篇 |
现状与发展 | 12篇 |
一般理论 | 60篇 |
预防医学 | 39171篇 |
眼科学 | 1762篇 |
药学 | 44989篇 |
466篇 | |
中国医学 | 8398篇 |
肿瘤学 | 7033篇 |
出版年
2023年 | 3543篇 |
2022年 | 5302篇 |
2021年 | 8491篇 |
2020年 | 9810篇 |
2019年 | 10337篇 |
2018年 | 9648篇 |
2017年 | 8338篇 |
2016年 | 7204篇 |
2015年 | 7389篇 |
2014年 | 15275篇 |
2013年 | 18791篇 |
2012年 | 13923篇 |
2011年 | 14596篇 |
2010年 | 11852篇 |
2009年 | 10525篇 |
2008年 | 10417篇 |
2007年 | 9836篇 |
2006年 | 8712篇 |
2005年 | 7166篇 |
2004年 | 5984篇 |
2003年 | 5127篇 |
2002年 | 3831篇 |
2001年 | 3438篇 |
2000年 | 2865篇 |
1999年 | 2311篇 |
1998年 | 2013篇 |
1997年 | 1846篇 |
1996年 | 1578篇 |
1995年 | 1503篇 |
1994年 | 1282篇 |
1993年 | 1030篇 |
1992年 | 994篇 |
1991年 | 919篇 |
1990年 | 742篇 |
1989年 | 644篇 |
1988年 | 631篇 |
1987年 | 539篇 |
1985年 | 1497篇 |
1984年 | 1958篇 |
1983年 | 1573篇 |
1982年 | 1549篇 |
1981年 | 1468篇 |
1980年 | 1280篇 |
1979年 | 1105篇 |
1978年 | 944篇 |
1977年 | 696篇 |
1976年 | 837篇 |
1975年 | 757篇 |
1974年 | 590篇 |
1973年 | 523篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
我国奶牛养殖规模不断扩大,奶业产值比重逐步提高,给奶牛疫病防治带来巨大压力。奶牛乳房炎及细菌性肺炎等呼吸系统疾病和细菌性肠炎等消化系统疾病最为常见,抗菌药物的使用成为主要防治手段。但抗菌药物的不当使用易使细菌产生耐药性,增加临床治疗的成本和难度,危害我国奶牛产业发展。本文对截至2021年7月我国和美国、英国、日本、欧盟批准用于奶牛的抗菌药物产品进行整理、统计与分析,包括抗菌药物的分类、剂型以及适应证等,旨在为我国奶牛用抗菌药物管理、合理用药和新兽药开发提供参考。 相似文献
3.
4.
目的:探讨项目管理在降低呼吸重症监护室(RICU)环境物品表面多重耐药菌检出率中的应用效果。方法:采用目的抽样方法,选取医院呼吸与危重症医学科RICU 17张编制床位、32处高频接触环境物品表面及42名工作人员为观察对象。2019年1月—2019年3月实施RICU常规管理,2019年4月—2019年6月实施项目管理。比较项目管理前后RICU各类别工作人员手卫生依从率、RICU环境物品表面清洁合格率及多重耐药菌检出率。结果:在项目管理后RICU各类别工作人员手卫生依从率均高于项目管理前(P<0.05);项目管理后RICU环境物品表面清洁合格率较项目管理前升高(P<0.05);项目管理后多重耐药菌(MDRO)病人床单位及病区办公区域环境物体表面的耐甲氧西林金黄色葡萄球菌(MRSA)和耐碳青霉烯鲍曼不动杆菌(CRAB)检出率均较项目管理前降低(P<0.05)。结论:项目管理可有效提高RICU各类别工作人员手卫生依从性及环境物品表面清洁合格率,降低RICU环境物品表面多重耐药菌检出率。 相似文献
5.
6.
【目的】 分析2019—2020年我国学者发表在SCIE收录期刊上的医学研究型论文撤稿原因及其特征,为更有针对性地防范我国医学领域学术不端行为发生、完善科研诚信体系提供参考。【方法】 在撤稿观察数据库(Retraction Watch Database)中检索2019—2020年撤稿的我国医学SCIE研究型论文,提取撤销论文标题、作者姓名和单位、载文期刊名称、期刊出版商、撤稿原因等信息。应用GraphPad Prism 8.3.0软件进行描述性统计分析,对撤销论文发表期刊的影响因子和撤稿率进行Spearman相关性分析。【结果】 2019—2020年,我国医学SCIE研究型论文累计撤稿479篇,撤稿原因主要为关注或问题、重复发表、研究错误等,具体撤稿理由包括数据问题、图片问题、方法与结果问题、作者无回应等。撤销论文分布于194种期刊,其中PLoS ONE、European Review for Medical and Pharmacological Sciences、Journal of Cellular Biochemistry、OncoTargets and Therapy、Biosciences Reports居撤销论文数量前5位,Springer Nature、Elsevier和PLoS居撤销论文出版商前3位。撤销论文载文期刊影响因子与期刊撤稿率呈负相关。【结论】 我国学者发表的医学类SCIE研究型论文因数据和图片等问题而被撤稿的概率较高,应加强我国医学领域科研诚信体系建设,减少学术不端行为发生。 相似文献
7.
Anna Maria Spera 《World Journal of Virology》2022,11(5):275-282
With a 5.3% of the global population involved, hepatitis B virus (HBV) is a major public health challenge requiring an urgent response. After a possible acute phase, the natural history of HBV infection can progress in chronicity. Patients with overt or occult HBV infection can undergo HBV reactivation (HBVr) in course of immunosuppressive treatments that, apart from oncological and hem-atological diseases, are also used in rheumatologic, gastrointestinal, neurological and dermatological settings, as well as to treat severe acute respiratory syndrome coronavirus 2 infection. The risk of HBV reactivation is related to the immune status of the patient and the baseline HBV infection condition. The aim of the present paper is to investigate the risk of HBVr in those not oncological settings in order to suggest strategies for preventing and treating this occurrence. The main studies about HBVr for patients with occult hepatitis B infection and chronic HBV infection affected by non-oncologic diseases eligible for immunosuppressive treatment have been analyzed. The occurrence of this challenging event can be reduced screening the population eligible for immunosuppressant to assess the best strategies according to any virological status. Further prospective studies are needed to increase data on the risk of HBVr related to newer immunomodulant agents employed in non-oncological setting. 相似文献
8.
9.
《Research in social & administrative pharmacy》2022,18(8):3284-3289
BackgroundAdverse drug reactions (ADRs) and adverse drug events (ADEs) in older people contribute to a significant proportion of hospital admissions and are common following discharge. Effective interventions are therefore required to combat the growing burden of preventable ADRs. The Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community Dwelling Patients (PADR-EC) score is a validated risk score developed to assess the risk of ADRs in people aged 65 years and older and has the potential to be utilised as part of an intervention to reduce ADRs.ObjectivesThis trial was designed to investigate the effectiveness of an intervention to reduce ADR incidence in older people and to obtain further information about ADRs and ADEs in the 12–24 months following hospital discharge.MethodsThe study is an open-label randomised-controlled trial to be conducted at the Royal Hobart Hospital, a 500-bed public hospital in Tasmania, Australia. Community-dwelling patients aged 65 years and older with an unplanned overnight admission to a general medical ward will be recruited. Following admission, the PADR-EC ADR score will be calculated by a research pharmacist, with the risk communicated to clinicians and discussed with participants. Following discharge, nominated general practitioners and community pharmacists will receive the risk score and related medication management advice to guide their ongoing care of the patient. Follow-up with participants will occur at 3 and 12 and 18 and 24 months to identify ADRs and ADEs. The primary outcome is moderate-severe ADRs at 12 months post-discharge, and will be analysed using the cumulative incidence proportion, survival analysis and Poisson regression.SummaryIt is hypothesised that the trial will reduce ADRs and ADEs in the intervention population. The study will also provide valuable data on post-discharge ADRs and ADEs up to 24 months post-discharge. 相似文献
10.
《European annals of otorhinolaryngology, head and neck diseases》2022,139(6):351-356
ObjectivesSystematic review of the scientific literature dedicated to treatment modalities and results for aural tuberculosis published since the start of the 21st century.Material and methodsSearch of the Medline, Cochrane and Embase databases for the period 2000 - 2020. Selection of articles in English, French and Spanish devoted to clinical cases and series documenting treatment of auricular tuberculosis. Extraction of data on pre-established files documenting treatment modalities and results. Reading of articles by two authors. Analysis performed according to SWiM guidelines, evaluating cure, tuberculosis-related death, treatment-related complications, improvement in facial palsy, and hearing sequelae rates.ResultsOne hundred and twenty eight articles: 118 case reports (159 patients) and 10 cohorts (177 patients) from 42 countries were analyzed. Female/male sex ratio was 1.2 with ages ranging from 1 month to 87 years. Medical treatment consisted in 5 to 24 months’ antitubercular antibiotic treatment using 2 to 8 antibiotics. Mastoidectomy, tympanoplasty and facial nerve decompression were associated to medical treatment in 64.7%, 17.4% and 6.2% of cases, respectively. Overall rates of cure, death, treatment-related complications, facial sequelae and hearing sequelae were 96.8%, 2%, 9.5%, 35.8% and 75.5%. In case reports, BCG vaccination did not appear to protect against facial palsy and severe intracranial complications (P > 0.6). There was no significant correlation (P > 0.3) between death and the clinical variables tested, and facial nerve decompression did not appear to influence outcome for facial function (P = 0.4).ConclusionMedical treatment is very effective but not without risk of death, complications and sequelae. It is the same as for pulmonary tuberculosis. Indications for and benefit of major auricular surgery during medical treatment deserve further studies. 相似文献